临床试验/NCT00454753

NCT00454753No Longer Available不适用

Expanded Access for Dasatinib

Bristol-Myers Squibb0 个研究点开始时间: 2007年4月2日最近更新: 2022年4月29日

相关药物

试验速览

阶段: 不适用
状态: No Longer Available
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

This is an expanded access designed to provide access to dasatinib for eligible participants.

研究设计

研究类型: Expanded Access

入排标准

入选标准

未提供

排除标准

未提供

研究者

发起方

Bristol-Myers Squibb

申办方类型

Industry

责任方

Sponsor

相似试验

No Longer Available

Expanded Access for Abatacept

NCT05170672Bristol-Myers Squibb

Expanded Access to UpadacitinibSpondyloarthritisAxial SpondyloarthritisNon-radiographic AxialNon Segmental VitiligoHidradenitis SuppurativaCrohn DiseaseUlcerative ColitisAtopic DermatitisRheumatoid ArthritisPsoriatic ArthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia Areata

NCT04159597AbbVie

Expanded Access for Apixaban

NCT05187286Bristol-Myers Squibb

Approved For Marketing

An Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA)Muscular Atrophy, Spinal

NCT04256265Genentech, Inc.

Expanded Access for Repotrectinib

NCT05926232Bristol-Myers Squibb